Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. has passed the listing hearing on the Hong Kong Stock Exchange, with Huatai International and CMB International as joint sponsors [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities, with a pipeline of innovative drugs under development [3] - The company has received approval from the National Medical Products Administration for 14 generic drugs and has established a pipeline of four innovative drugs [3] - The revenue during the track record period comes from 13 approved products, primarily in therapeutic areas that account for over 25% of China's total pharmaceutical sales in 2023 [3] Product Portfolio - The company employs a dual-track model, focusing on both generic drugs and innovative drugs in development [3] - The product portfolio includes approved generic drugs for digestive, cardiovascular, endocrine, neurological, and inflammatory diseases [3] - Four of the approved generic drugs are included in the National Volume-Based Procurement (VBP) program, contributing significantly to revenue [3] Financial Performance - Revenue figures for Haixi New Drug are as follows: approximately RMB 212 million in 2022, RMB 317 million in 2023, RMB 467 million in 2024, and RMB 249 million for the five months ending May 31, 2025 [7][8] - Profit figures for the same periods are approximately RMB 69 million, RMB 117 million, RMB 136 million, and RMB 90 million respectively [7][8] - The company’s major products include Anbili® (RMB 146 million revenue in 2024, 25.7% market share), Haihuaitong® (RMB 187 million revenue in 2024, 59.3% market share), and Ruian Tuo® (RMB 48 million revenue in 2024, 16.7% market share) [3][4]
新股消息 | 海西新药通过港交所聆讯 四款仿制药入选国家带量采购计划
智通财经网·2025-09-29 22:50